Synopsis
Synopsis
0
VMF
0
Australia
Annual Reports
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Dichlofenal
2. Diclofenac
3. Diclofenac Potassium
4. Diclofenac, Sodium
5. Diclonate P
6. Diclophenac
7. Dicrofenac
8. Feloran
9. Gp 45,840
10. Gp-45,840
11. Gp45,840
12. Novapirina
13. Orthofen
14. Orthophen
15. Ortofen
16. Sodium Diclofenac
17. Sr 38
18. Sr-38
19. Sr38
20. Voltaren
21. Voltarol
1. Qtg126297q
2. Voltaren
3. 15307-79-6
4. Diclofenac Sodium Salt
5. Sodium Diclofenac
6. Prophenatin
7. Neriodin
8. Diclophenac Sodium
9. Abitren
10. Solaraze
11. Diclofenac (sodium)
12. Gp 45840
13. Benfofen
14. Dyloject
15. Ecofenac
16. Feloran
17. Pennsaid
18. Orthophen
19. Voltarol
20. Voltaren-xr
21. Diclophlogont
22. Duravolten
23. Novapirina
24. Primofenac
25. Dealgic
26. Deflamat
27. Delphinac
28. Diclomax
29. Dicloreum
30. Effekton
31. Lexobene
32. Rewodina
33. Voldal
34. Xenid
35. Sodium (o-(2,6-dichloroanilino)phenyl)acetate
36. Arthrotec
37. Olfen
38. Benzeneacetic Acid, 2-((2,6-dichlorophenyl)amino)-, Monosodium Salt
39. Sodium (o-((2,6-dichlorophenyl)amino)phenyl)acetate
40. Sodium {2-[(2,6-dichlorophenyl)amino]phenyl}acetate
41. (o-(2,6-dichloroanilino)phenyl)acetic Acid Sodium Salt
42. Sodium 2-(2-((2,6-dichlorophenyl)amino)phenyl)acetate
43. Mls000028386
44. Chebi:4509
45. (o-(2,6-dichloroanilino)phenyl)acetic Acid Monosodium Salt
46. 2-[(2,6-dichlorophenyl)amino]benzeneacetic Acid Sodium Salt
47. 2-((2,6-dichlorophenyl)amino)benzeneacetic Acid Monosodium Salt
48. Benzeneacetic Acid, 2-[(2,6-dichlorophenyl)amino]-, Monosodium Salt
49. Sodium;2-[2-(2,6-dichloroanilino)phenyl]acetate
50. Nsc-756725
51. Ncgc00017082-02
52. Anthraxiton
53. Allvoran
54. Batafil
55. Delimon
56. Delphimix
57. Dichronic
58. Gp-45840
59. Kriplex
60. Ortofen
61. Smr000058567
62. Tsudohmin
63. Valetan
64. Voltarene
65. Vonafec
66. Blesin
67. Urigon
68. Vurdon
69. Solaraze (tn)
70. Cas-15307-79-6
71. Diclofenac Sodium 100 Microg/ml In Acetonitrile
72. Dsstox_cid_17208
73. Dsstox_rid_79308
74. Voltaren Ophthalmic
75. Dsstox_gsid_37208
76. Diclofenac Diethylammonium
77. Sodium (2-((2,6-dichlorophenyl)amino)phenyl)acetate
78. Diclofenac Diethylamine Salt
79. Assaren
80. Voltaren Gel
81. Benzeneacetic Acid, 2-[(2,6-dichlorophenyl)amino]-, Monosodium Salt [cas]
82. Smr000449318
83. Ccris 1909
84. Einecs 239-346-4
85. Ba 47210
86. Diclofenac Sodium Injection
87. Sodium 2-[2-[(2,6-dichlorophenyl)amino]phenyl]acetate
88. Diclofenac Sodium Topical Gel
89. Berifen
90. Dic075v
91. Rhumalgan
92. Diclofenac Sod
93. Unii-qtg126297q
94. Sodium 2-(2-(2,6-dichlorophenylamino)phenyl)acetate
95. Tds 943
96. Sodium (o-(2,6-dichloroanilino)phenyl) Acetate
97. Voltaren (tn)
98. Diclofenac Sodium [usan:usp:jan]
99. Mfcd00082251
100. Dicloflex
101. Diclofenac Sodium,(s)
102. Opera_id_564
103. Sodium Dichlofenac
104. Lopac-d-6899
105. Ec 239-346-4
106. Chembl1034
107. Schembl24009
108. Mls000758255
109. Mls001148587
110. Mls001423970
111. Mls002222163
112. Mls003882590
113. Spectrum1500237
114. Diclofenac Sodium [jan]
115. Diclofenac Sodium (jp17/usp)
116. Diclofenac Sodium [usan]
117. Dtxsid3037208
118. Diclofenac For System Suitability
119. Hms500n14
120. Diclofenac Sodium [vandf]
121. Diclofenac Sodium [mart.]
122. Regid_for_cid_5018304
123. Acetic Acid, O-(2,6-dichloroanilino)phenyl-, Monosodium Salt
124. Hms1569h10
125. Hms1920e16
126. Hms2051m05
127. Hms2091m06
128. Hms2096h10
129. Hms2235o06
130. Hms2236d03
131. Hms3261i04
132. Hms3369k11
133. Hms3371j05
134. Hms3393m05
135. Hms3650b13
136. Hms3655a22
137. Hms3713h10
138. Hms3884c16
139. Kuc112363n
140. Diclofenac Sodium [usp-rs]
141. Diclofenac Sodium [who-dd]
142. Bcp02915
143. Diclofenac Sodium Salt [mi]
144. Tox21_110770
145. Tox21_300265
146. Tox21_500441
147. Ccg-39754
148. S1903
149. Stk400073
150. Akos000310014
151. Akos005267222
152. Akos024278942
153. Diclofenac Sodium [green Book]
154. Tox21_110770_1
155. Ac-1487
156. Bcp9000605
157. Ccg-100765
158. Diclofenac Sodium [orange Book]
159. Ks-5038
160. Lp00441
161. Nc00015
162. Nsc 756725
163. Sdccgsbi-0050426.p002
164. Diclofenac Sodium [ep Monograph]
165. Ksc-322-017
166. Diclofenac Sodium [usp Monograph]
167. Ncgc00015361-01
168. Ncgc00015361-02
169. Ncgc00015361-03
170. Ncgc00015361-04
171. Ncgc00017082-01
172. Ncgc00017082-03
173. Ncgc00021125-03
174. Ncgc00093858-01
175. Ncgc00093858-02
176. Ncgc00094648-01
177. Ncgc00094648-02
178. Ncgc00253928-01
179. Ncgc00261126-01
180. Bd166162
181. Cpd000449318
182. Hy-15037
183. Bcp0726000303
184. Arthrotec Component Diclofenac Sodium
185. B1457
186. D-181
187. D2508
188. Eu-0100441
189. Ft-0624732
190. Sodium 2-(2,6-dichloroanilino)phenylacetate
191. Sw196404-3
192. Sodium 2-(2,6-dichloroanilino)-phenylacetate
193. Bim-0051341.0001
194. D 6899
195. D00904
196. D78205
197. Diclofenac Sodium Component Of Arthrotec
198. A809387
199. Sodium 2-[(2,6-dichlorophenyl)amino]phenylacetate
200. Q-200965
201. Sodium 2-[(2,6-dichlorophenyl)-amino]phenylacetate
202. Sodium;2-[2-(2,6-dichloroanilino)phenyl]acetate.
203. 2-(2,6-dichloroanilino)phenylacetic Acid Sodium Salt
204. Q12430631
205. Sodium 2-[(2,6-dichlorophenyl)-amino]-phenyl-acetate
206. Sodium 2-[(2,6-dichlorophenyl)-amino]-phenylacetate
207. Sodium;2-[2-(2,6-dichloroanilino)phenyl]acetic Acid
208. 2-[(2,6-dichlorophenyl)amino]benzeneacetic Acid Sodium
209. Diclofenac Sodium 1.0 Mg/ml In Methanol (as Free Acid)
210. Benzeneacetic Acid, 2-[(2,6-dichlorophenyl)amino]-, Sodium Salt (1:1)
| Molecular Weight | 318.1 g/mol |
|---|---|
| Molecular Formula | C14H10Cl2NNaO2 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 4 |
| Exact Mass | 316.9986282 g/mol |
| Monoisotopic Mass | 316.9986282 g/mol |
| Topological Polar Surface Area | 52.2 Ų |
| Heavy Atom Count | 20 |
| Formal Charge | 0 |
| Complexity | 310 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Diclofenac sodium |
| Drug Label | Diclofenac sodium delayed-release tablets are a benzeneacetic acid derivative. The chemical name is 2-[(2,6-dichlorophenyl)amino] benzeneacetic acid, monosodium salt. The molecular weight is 318.13. Its molecular formula is C14H10Cl2NNaO2, and it has... |
| Active Ingredient | Diclofenac sodium |
| Dosage Form | Gel; Tablet, extended release; Solution/drops; Spray; Tablet, delayed release; Solution |
| Route | Topical; Ophthalmic; oral; Oral |
| Strength | 75mg; 100mg; 25mg; 1.5%; 50mg; 0.1%; 3% |
| Market Status | Tentative Approval; Prescription |
| Company | Watson Labs; Nexus Pharms; Mylan Pharms; Actavis Elizabeth; Igi Labs; Paddock; Valeant Intl; Apotex; Bausch And Lomb; Alcon Pharms; Tolmar; Unique Pharm Labs; Carlsbad; Sandoz; Mylan; Dexcel; Akorn |
| 2 of 2 | |
|---|---|
| Drug Name | Diclofenac sodium |
| Drug Label | Diclofenac sodium delayed-release tablets are a benzeneacetic acid derivative. The chemical name is 2-[(2,6-dichlorophenyl)amino] benzeneacetic acid, monosodium salt. The molecular weight is 318.13. Its molecular formula is C14H10Cl2NNaO2, and it has... |
| Active Ingredient | Diclofenac sodium |
| Dosage Form | Gel; Tablet, extended release; Solution/drops; Spray; Tablet, delayed release; Solution |
| Route | Topical; Ophthalmic; oral; Oral |
| Strength | 75mg; 100mg; 25mg; 1.5%; 50mg; 0.1%; 3% |
| Market Status | Tentative Approval; Prescription |
| Company | Watson Labs; Nexus Pharms; Mylan Pharms; Actavis Elizabeth; Igi Labs; Paddock; Valeant Intl; Apotex; Bausch And Lomb; Alcon Pharms; Tolmar; Unique Pharm Labs; Carlsbad; Sandoz; Mylan; Dexcel; Akorn |
Treatment of inflammation, Treatment of pain
Anti-Inflammatory Agents, Non-Steroidal
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)
Cyclooxygenase Inhibitors
Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes. (See all compounds classified as Cyclooxygenase Inhibitors.)

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
The launch of Dr. Reddy’s Diclofenac Sodium Topical Gel, 1% (OTC), is an important addition to the Pain/ Analgesics portfolio of OTC products, and represents the continued commitment to the Private Label OTC space.
Lead Product(s): Diclofenac Sodium,Inapplicable
Therapeutic Area: Musculoskeletal Brand Name: Diclofenac Sodium-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 09, 2020
Lead Product(s) : Diclofenac Sodium,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The launch of Dr. Reddy’s Diclofenac Sodium Topical Gel, 1% (OTC), is an important addition to the Pain/ Analgesics portfolio of OTC products, and represents the continued commitment to the Private Label OTC space.
Product Name : Diclofenac Sodium-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 09, 2020
Details:
Diclofenac Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Diclofenac Sodium,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 11, 2024

Lead Product(s) : Diclofenac Sodium,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Diclofenac Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 11, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Voltaren (Diclofenac Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pain.
Lead Product(s): Diclofenac Sodium,Inapplicable
Therapeutic Area: Neurology Brand Name: Voltaren
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 23, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Diclofenac Sodium,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Voltaren (Diclofenac Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pain.
Product Name : Voltaren
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 23, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
DARE-PDM1 (diclofenac) is a vaginal hydrogel which inhibits Cox-1 and Cox-2. It is being evaluated in phase 1 clinical trials for the treatment of primary dysmenorrhea.
Lead Product(s): Diclofenac Sodium,Inapplicable
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 20, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Diclofenac Sodium,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from ...
Details : DARE-PDM1 (diclofenac) is a vaginal hydrogel which inhibits Cox-1 and Cox-2. It is being evaluated in phase 1 clinical trials for the treatment of primary dysmenorrhea.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 20, 2023

Details:
Diclofenac Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Diclofenac Sodium,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 01, 2023

Lead Product(s) : Diclofenac Sodium,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Diclofenac Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 01, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
DARE-PDM1 is a novel delivery of the diclofenac sodium, a NSAID drug which inhibits COX-1 and COX-2 responsible for producing PGs which contributes in inflammation and pain signalling. It uses Daré’s proprietary hydrogel technology targeted at treating primary dysmenorrhea.
Lead Product(s): Diclofenac Sodium,Inapplicable
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 22, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Diclofenac Sodium,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment ...
Details : DARE-PDM1 is a novel delivery of the diclofenac sodium, a NSAID drug which inhibits COX-1 and COX-2 responsible for producing PGs which contributes in inflammation and pain signalling. It uses Daré’s proprietary hydrogel technology targeted at treatin...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 22, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Because there are currently no FDA-approved vaginal diclofenac treatment options for primary dysmenorrhea, DARE-PDM1 has the potential to be a first-in-category product.
Lead Product(s): Diclofenac Sodium,Inapplicable
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 12, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Diclofenac Sodium,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Because there are currently no FDA-approved vaginal diclofenac treatment options for primary dysmenorrhea, DARE-PDM1 has the potential to be a first-in-category product.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 12, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Diclofenac topical solution is used to treat pain and swelling caused by osteoarthritis of the knees. Diclofenac Sodium Topical Solution, 2% w/w (RLD PENNSAID®) had estimated annual sales of USD 509 million in the U.S.
Lead Product(s): Diclofenac Sodium,Inapplicable
Therapeutic Area: Musculoskeletal Brand Name: Diclofenac Sodium-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 09, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Diclofenac Sodium,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Launches Authorized Generic Version of PENNSAID® 2% w/w in the United States
Details : Diclofenac topical solution is used to treat pain and swelling caused by osteoarthritis of the knees. Diclofenac Sodium Topical Solution, 2% w/w (RLD PENNSAID®) had estimated annual sales of USD 509 million in the U.S.
Product Name : Diclofenac Sodium-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 09, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Diclofenac Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Wounds and Injuries.
Lead Product(s): Diclofenac Sodium,Inapplicable
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 26, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Diclofenac Sodium,Inapplicable
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Diclofenac Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Wounds and Injuries.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 26, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Diclofenac Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoarthritis, Knee.
Lead Product(s): Diclofenac Sodium,Inapplicable
Therapeutic Area: Musculoskeletal Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 24, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Diclofenac Sodium,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Diclofenac Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoarthritis, Knee.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 24, 2020

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Dosage Form : Capsule, Granule / Pellet, Tablet
Grade : Oral
Category : Coating Systems & Additives, Controlled & Modified Release, Solubilizers
Brand Name : EUDRAGIT® L 100-55
Application : Coating Systems & Additives, Controlled & Modified Release, Solubilizers
Excipient Details : EUDRAGIT® L 100-55 (powder) is used in delayed release coatings to enhance solubility of poorly soluble drugs such as tablets, capsules & granules.
Pharmacopoeia Ref : NA
Technical Specs : NA
Ingredient(s) : Methacrylic Acid - Ethyl Acrylate Copolymer
Dosage Form : Tablet
Grade : Oral
Category : Coating Systems & Additives, Controlled & Modified Release
Application : Coating Systems & Additives, Controlled & Modified Release
Excipient Details : ACTILLETS are microcrystalline cellulose spheres developed using advanced drug delivery technology to enable effective loading & coating of particles.
Pharmacopoeia Ref : NA
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose Excipients
Grade : Oral
Category : Coating Systems & Additives, Film Formers & Plasticizers
Brand Name : EUDRAGIT® L 30 D-55
Application : Coating Systems & Additives, Film Formers & Plasticizers
Excipient Details : EUDRAGIT® L 30 D-55 (aqueous dispersion) is a delayed release polymer used as coating and film former in tablets, capsules, granules etc.
Pharmacopoeia Ref : NA
Technical Specs : NA
Ingredient(s) : Methacrylic Acid - Ethyl Acrylate Copolymer
Grade : Not Available
Category : Coating Systems & Additives, Film Formers & Plasticizers
Dosage Form : Emulsion, Tablet
Grade : Oral, Ophthalmic
Category : Disintegrants & Superdisintegrants, Emulsifying Agents, Film Formers & Plasticizers, Thickeners and Stabilizers
Brand Name : Hydroxypropyl Methyl Cellulose
Application : Disintegrants & Superdisintegrants, Emulsifying Agents, Film Formers & Plasticizers, Thickeners and Stabilizers
Excipient Details : Hydroxypropyl Methyl Cellulose is used as a film-former, disintegrant, thickener, and emulsifier in tablets, emulsions, and ophthalmic formulations.
Brand Name : Hydroxypropyl Methyl Cellulose
Application : Coating Systems & Additives
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Dosage Form : Tablet
Grade : Oral
Category : Coating Systems & Additives, Controlled & Modified Release
Application : Coating Systems & Additives, Controlled & Modified Release
Excipient Details : Ecopol L 100 is used as an enteric/delayed release coating system and for drug delivery in the small intestine.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Methacrylic Acid Methyl Methacrylate Copolymer
Application : Coating Systems & Additives
Excipient Details : Acrycoat L 12.5 is used as an enteric coated Drug delivery system.
Pharmacopoeia Ref : Ph.Eur.: Methacrylic Acid - Me...
Technical Specs : Not Available
Ingredient(s) : Methacrylic Acid Methyl Methacrylate Copolymer
Grade : Oral
Category : Coating Systems & Additives, Controlled & Modified Release, Solubilizers
Brand Name : Lumacril L-100D 55
Application : Coating Systems & Additives, Controlled & Modified Release, Solubilizers
Excipient Details : Lumacril L-100D 55 is an anionic copolymer used in delayed & sustained release coatings to enhance solubility for poorly soluble drugs in OSDs.
Pharmacopoeia Ref : USP-NF, Ph.Eur, BP, JP
Technical Specs : NA
Ingredient(s) : Methacrylic Acid - Ethyl Acrylate Copolymer
Global Sales Information
Market Place
Reply
23 Dec 2025
Reply
27 Sep 2025
Reply
08 Sep 2025
Reply
11 Jun 2025
Reply
18 Mar 2025
Reply
04 Feb 2025
Reply
16 Jan 2025
Reply
26 Dec 2024
Reply
23 Nov 2024
Reply
20 Jun 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
Patent Expiration Date : 2027-10-17
US Patent Number : 9101591
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 204623
Patent Use Code : U-1488
Delist Requested :
Patent Use Description : USE OF TOPICAL DICLOFE...
Patent Expiration Date : 2027-10-17

Patent Expiration Date : 2027-10-17
US Patent Number : 9220784
Drug Substance Claim :
Drug Product Claim :
Application Number : 204623
Patent Use Code : U-1488
Delist Requested :
Patent Use Description : USE OF TOPICAL DICLOFE...
Patent Expiration Date : 2027-10-17

Patent Expiration Date : 2029-07-10
US Patent Number : 8741956
Drug Substance Claim :
Drug Product Claim :
Application Number : 204623
Patent Use Code : U-1435
Delist Requested :
Patent Use Description : COMBINATION USE OF TOP...
Patent Expiration Date : 2029-07-10

Patent Expiration Date : 2029-07-10
US Patent Number : 9415029
Drug Substance Claim :
Drug Product Claim :
Application Number : 204623
Patent Use Code : U-1614
Delist Requested :
Patent Use Description : USE OF TOPICAL DICLOFE...
Patent Expiration Date : 2029-07-10

Patent Expiration Date : 2030-08-09
US Patent Number : 8546450
Drug Substance Claim :
Drug Product Claim :
Application Number : 204623
Patent Use Code : U-1435
Delist Requested :
Patent Use Description : COMBINATION USE OF TOP...
Patent Expiration Date : 2030-08-09

Patent Expiration Date : 2027-10-17
US Patent Number : 9339552
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 204623
Patent Use Code : U-1488
Delist Requested :
Patent Use Description : USE OF TOPICAL DICLOFE...
Patent Expiration Date : 2027-10-17

Patent Expiration Date : 2029-07-10
US Patent Number : 8618164
Drug Substance Claim :
Drug Product Claim :
Application Number : 204623
Patent Use Code : U-1477
Delist Requested :
Patent Use Description : USE OF TOPICAL DICLOFE...
Patent Expiration Date : 2029-07-10

Patent Expiration Date : 2029-07-10
US Patent Number : 8217078
Drug Substance Claim :
Drug Product Claim :
Application Number : 20947
Patent Use Code : U-1248
Delist Requested :
Patent Use Description : USE OF TOPICAL DICLOFE...
Patent Expiration Date : 2029-07-10

Patent Expiration Date : 2030-08-09
US Patent Number : 8546450
Drug Substance Claim :
Drug Product Claim :
Application Number : 20947
Patent Use Code : U-1435
Delist Requested :
Patent Use Description : COMBINATION USE OF TOP...
Patent Expiration Date : 2030-08-09

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
85
PharmaCompass offers a list of Diclofenac Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Diclofenac Sodium manufacturer or Diclofenac Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Diclofenac Sodium manufacturer or Diclofenac Sodium supplier.
PharmaCompass also assists you with knowing the Diclofenac Sodium API Price utilized in the formulation of products. Diclofenac Sodium API Price is not always fixed or binding as the Diclofenac Sodium Price is obtained through a variety of data sources. The Diclofenac Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Voltaren Gel manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Voltaren Gel, including repackagers and relabelers. The FDA regulates Voltaren Gel manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Voltaren Gel API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Voltaren Gel manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Voltaren Gel supplier is an individual or a company that provides Voltaren Gel active pharmaceutical ingredient (API) or Voltaren Gel finished formulations upon request. The Voltaren Gel suppliers may include Voltaren Gel API manufacturers, exporters, distributors and traders.
click here to find a list of Voltaren Gel suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Voltaren Gel DMF (Drug Master File) is a document detailing the whole manufacturing process of Voltaren Gel active pharmaceutical ingredient (API) in detail. Different forms of Voltaren Gel DMFs exist exist since differing nations have different regulations, such as Voltaren Gel USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Voltaren Gel DMF submitted to regulatory agencies in the US is known as a USDMF. Voltaren Gel USDMF includes data on Voltaren Gel's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Voltaren Gel USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Voltaren Gel suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Voltaren Gel Drug Master File in Japan (Voltaren Gel JDMF) empowers Voltaren Gel API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Voltaren Gel JDMF during the approval evaluation for pharmaceutical products. At the time of Voltaren Gel JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Voltaren Gel suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Voltaren Gel Drug Master File in Korea (Voltaren Gel KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Voltaren Gel. The MFDS reviews the Voltaren Gel KDMF as part of the drug registration process and uses the information provided in the Voltaren Gel KDMF to evaluate the safety and efficacy of the drug.
After submitting a Voltaren Gel KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Voltaren Gel API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Voltaren Gel suppliers with KDMF on PharmaCompass.
A Voltaren Gel CEP of the European Pharmacopoeia monograph is often referred to as a Voltaren Gel Certificate of Suitability (COS). The purpose of a Voltaren Gel CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Voltaren Gel EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Voltaren Gel to their clients by showing that a Voltaren Gel CEP has been issued for it. The manufacturer submits a Voltaren Gel CEP (COS) as part of the market authorization procedure, and it takes on the role of a Voltaren Gel CEP holder for the record. Additionally, the data presented in the Voltaren Gel CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Voltaren Gel DMF.
A Voltaren Gel CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Voltaren Gel CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Voltaren Gel suppliers with CEP (COS) on PharmaCompass.
A Voltaren Gel written confirmation (Voltaren Gel WC) is an official document issued by a regulatory agency to a Voltaren Gel manufacturer, verifying that the manufacturing facility of a Voltaren Gel active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Voltaren Gel APIs or Voltaren Gel finished pharmaceutical products to another nation, regulatory agencies frequently require a Voltaren Gel WC (written confirmation) as part of the regulatory process.
click here to find a list of Voltaren Gel suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Voltaren Gel as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Voltaren Gel API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Voltaren Gel as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Voltaren Gel and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Voltaren Gel NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Voltaren Gel suppliers with NDC on PharmaCompass.
Voltaren Gel Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Voltaren Gel GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Voltaren Gel GMP manufacturer or Voltaren Gel GMP API supplier for your needs.
A Voltaren Gel CoA (Certificate of Analysis) is a formal document that attests to Voltaren Gel's compliance with Voltaren Gel specifications and serves as a tool for batch-level quality control.
Voltaren Gel CoA mostly includes findings from lab analyses of a specific batch. For each Voltaren Gel CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Voltaren Gel may be tested according to a variety of international standards, such as European Pharmacopoeia (Voltaren Gel EP), Voltaren Gel JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Voltaren Gel USP).